Formulary
NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Formulary Update

Formulary Update (Dec 2014)

Additions to the GGC Adult Formulary

Greater Glasgow and Clyde Area Drug and Therapeutics Committee (ADTC) met on 8th December 2014 and added the following medicines/indications/ formulations to the GGC Formulary.  Additions are to the Total Formulary unless specified otherwise.  For brevity, some indications may be shortened.  For the full detail of the indication, see the relevant SMC advice.

Aflibercept intravitral injection (Eylea®) for the treatment of visual impairment due to diabetic macular oedema (DMO) in adults is included in the GGC Formulary for the indication in question.  It is restricted to specialist use for the treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline

For relevant SMC advice click here

Brinzolamide and brimonidine eye drops (Simbrinza®) for the decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction is included in the GGC Formulary for the indication in question.  It is restricted to specialist initiation.

For relevant SMC advice click here

Colecalciferol 25,000 units oral solution (Invita D3®) for the prevention and treatment of vitamin D deficiency and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency is included in the GGC Formulary for the indication in question, subject to the completion of a plan to implement safe use of this preparation due to potential risk in use where the oral ampoule may be mistaken for injectable product.

For relevant SMC advice click here

Clindamycin and tretinoin gel (Treclin®) for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older is included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Daclatasvir tablets (Daklinza®) for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults is included in the GGC Formulary for the indication in question. It is restricted to specialist use in accordance with local guidelines, in patients with significant fibrosis (Metavir scores F3-F4) or compensated cirrhosis.

For relevant SMC advice click here

Dolutegravir, abacavir, lamivudine tablets (Triumeq®) for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg is included in the GGC Formulary for the indication in question. It is restricted to use by HIV specialists.

For relevant SMC advice click here

Everolimus tablets (Afinitor®) for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy is included in the GGC Formulary for the indication in question. It is restricted to specialist use in accordance with regional protocol.

For relevant SMC advice click here

Indacaterol maleate and glycopyrronium bromide inhaler (Ultibro® Breezhaler®) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) is included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Ipilimumab infusion (Yervoy®) for the treatment of advanced (unresectable or metastatic) melanoma in adults (first-line use) is included in the GGC Formulary for the indication in question. It is restricted to specialist use in accordance with regional protocol.

For relevant SMC advice click here

Obinutuzumab infusion (Gazyvaro®) for use in combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy is included in the GGC Formulary for the indication in question. It is restricted to specialist use in accordance with regional protocol.

For relevant SMC advice click here

Pemetrexed infusion (Alimta®) for use as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy is included in the GGC Formulary for the indication in question. It is restricted to specialist use in accordance with regional protocol.

For relevant SMC advice click here

Pomalidomide hard capsules (Imnovid®) for use in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy is included in the GGC Formulary for the indication in question. It is restricted to specialist use in accordance with regional protocol.

For relevant SMC advice click here

Riociguat tablets (Adempas®) for chronic thromboembolic pulmonary hypertension (CTEPH): Treatment of adult patients with World Health Organisation (WHO) functional class II to III with

  1. inoperable CTEPH
  2. persistent or recurrent CTEPH after surgical treatment,

to improve exercise capacity is included in the GGC Formulary for the indication in question.  It is restricted to initiation and prescribing only by specialists in the Scottish Pulmonary Vascular Unit for use in patients in whom a PDE5 inhibitor is inappropriate, not tolerated, or ineffective.

For relevant SMC advice click here

Saxagliptin tablets (Onglyza®) for use in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control is included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Umeclidinium inhaler (Incruse®) for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) is included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

New medicines, indications and formulations not included in the GGC Adult Formulary or GGC Paediatric Formulary

The following are not included in the GGC Adult Formulary following the latest ADTC meeting. Where the reason is other than not recommended advice from SMC it is noted.  NB: these medicines may be included in the Formulary for other indications or for other formulations.  Please refer to Formulary.

Denosumab injection (Prolia®) for osteoporosis in men at increased risk of fractures is not included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Mifepristone and misoprostol tablets/vaginal tablets (Medabon®) for the medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea is not included in the GGC Formulary for the indication in question as the clinicians do not support inclusion.  The combined pack presentation offered no advantage over existing formulary choices and was considered to introduce additional risk. This presentation will not be stocked in relevant departments in NHSGGC.

For relevant SMC advice click here

Pertuzumab infusion (Perjeta®) for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease is not included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Telavancin hydrochloride infusion (Vibativ®) for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) is not included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Tocilizumab infusion (RoActemra®) for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate is not included in the GGC Formulary for the indication in question.

For relevant SMC advice click here

Voriconazole tablets/infusion/oral suspension (Vfend®) for prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients is not included in the GGC Formulary for the indication in question.

For relevant SMC advice click here